SI-BONE Dirección

Dirección controles de criterios 3/4

El CEO de SI-BONE es Laura Francis , nombrado en Apr 2021, tiene una permanencia de 3.58 años. compensación anual total es $3.71M, compuesta por 16.8% salario y 83.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.84% de las acciones de la empresa, por valor de €4.27M. La antigüedad media del equipo directivo y de la junta directiva es de 3.6 años y 13.9 años, respectivamente.

Información clave

Laura Francis

Chief Executive Officer (CEO)

US$3.7m

Compensación total

Porcentaje del salario del CEO	16.8%
Permanencia del CEO	3.6yrs
Participación del CEO	0.8%
Permanencia media de la dirección	3.6yrs
Promedio de permanencia en la Junta Directiva	13.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Laura Francis en comparación con los beneficios de SI-BONE?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$37m
Jun 30 2024	n/a	n/a	-US$41m
Mar 31 2024	n/a	n/a	-US$43m
Dec 31 2023	US$4m	US$622k	-US$43m
Sep 30 2023	n/a	n/a	-US$44m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	-US$55m
Dec 31 2022	US$5m	US$604k	-US$61m
Sep 30 2022	n/a	n/a	-US$65m
Jun 30 2022	n/a	n/a	-US$66m
Mar 31 2022	n/a	n/a	-US$62m
Dec 31 2021	US$3m	US$527k	-US$57m
Sep 30 2021	n/a	n/a	-US$51m
Jun 30 2021	n/a	n/a	-US$45m
Mar 31 2021	n/a	n/a	-US$43m
Dec 31 2020	US$2m	US$386k	-US$44m
Sep 30 2020	n/a	n/a	-US$44m
Jun 30 2020	n/a	n/a	-US$46m
Mar 31 2020	n/a	n/a	-US$42m
Dec 31 2019	US$2m	US$375k	-US$38m
Sep 30 2019	n/a	n/a	-US$35m
Jun 30 2019	n/a	n/a	-US$28m
Mar 31 2019	n/a	n/a	-US$23m
Dec 31 2018	US$734k	US$319k	-US$17m
Sep 30 2018	n/a	n/a	-US$17m
Jun 30 2018	n/a	n/a	-US$18m
Mar 31 2018	n/a	n/a	-US$21m
Dec 31 2017	US$518k	US$302k	-US$23m

Compensación vs. Mercado: La compensación total de Laura($USD3.71M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.03M).

Compensación vs. Ingresos: La compensación de Laura ha sido consistente con los resultados de la empresa en el último año.

CEO

Laura Francis (57 yo)

3.6yrs

Permanencia

US$3,713,871

Compensación

Ms. Laura A. Francis, MBA, serves as Chief Executive Officer and Director at SI-BONE, Inc. since April 18, 2021. She was Chief Financial Officer of SI-Bone Inc. since May 26, 2015 until April 18, 2021 and...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Laura Francis	CEO & Director	3.6yrs	US$3.71m	0.84% € 4.3m
Anshul Maheshwari	Chief Financial Officer	3.6yrs	US$1.86m	0.17% € 846.8k
Anthony Recupero	President of Commercial Operations	8.3yrs	US$2.06m	0.23% € 1.2m
Jeff Bertolini	Senior Vice President of Operations & Information Technology	2.3yrs	sin datos	sin datos
Scott Yerby	Senior VP of Engineering & CTO	no data	sin datos	sin datos
Saqib Iqbal	Director of FP&A and Investor Relations	no data	sin datos	sin datos
Michael Pisetsky	Chief Business & Legal Affairs Officer	8.3yrs	sin datos	sin datos
Aimee Einstein	Vice President of People & Culture	2.8yrs	sin datos	sin datos
Daniel Cher	Senior Vice President of Clinical & Regulatory Affairs	3.4yrs	sin datos	sin datos
W. Reckling	Chief Medical Officer & VP of Medical Affairs	no data	sin datos	sin datos
Nikolas Kerr	Senior Vice President of Product	3.6yrs	sin datos	sin datos
Troy Wahlenmaier	Senior Vice President of US Sales	less than a year	sin datos	sin datos

3.6yrs

Permanencia media

56.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2K3 se considera experimentado (3.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Laura Francis	CEO & Director	3.6yrs	US$3.71m	0.84% € 4.3m
Timothy Davis	Lead Independent Director	16.6yrs	US$211.30k	0.092% € 465.6k
Gregory Hinckley	Independent Director	13.8yrs	US$191.30k	0.38% € 1.9m
Jeryl Hilleman	Independent Director	4.9yrs	US$206.30k	0.025% € 126.5k
John Freund	Independent Director	11.8yrs	US$188.30k	0.31% € 1.6m
Ralph Rashbaum	Member of Medical Advisory Board	14.8yrs	sin datos	sin datos
Steven Garfin	Member of Medical Advisory Board	14.8yrs	sin datos	sin datos
Frank Phillips	Member of Medical Advisory Board	14.8yrs	sin datos	sin datos
Jeffrey Dunn	Executive Chairman	16.6yrs	US$551.18k	0.26% € 1.3m
A. Shamie	Member of Medical Advisory Board	13.9yrs	sin datos	sin datos
Mika Nishimura	Independent Director	3.7yrs	US$188.30k	0.046% € 233.4k
Jonathan Hyde	Member of Surgeon Advisory Board	no data	sin datos	sin datos

13.9yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de 2K3 son experimentados ( 13.9 años antigüedad media).

SI-BONE Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

CEO & Director recently sold €126k worth of stock

Insufficient new directors

SI-BONE, Inc., Annual General Meeting, Jun 25, 2024

CEO & Director recently sold €751k worth of stock

Executive Chairman recently sold €130k worth of stock

CEO & Director recently sold €173k worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.25 loss in 3Q 2023)

SI-BONE, Inc. Updates Financial Guidance for the Year 2024

SI-BONE, Inc. Updates Financial Guidance for the Year 2024

SI-BONE, Inc. to Report Q3, 2024 Results on Nov 12, 2024

SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation

CEO & Director recently sold €126k worth of stock

Second quarter 2024 earnings released: US$0.22 loss per share (vs US$0.30 loss in 2Q 2023)

SI-BONE, Inc. Revises Financial Guidance for 2024

New minor risk - Share price stability

SI-BONE, Inc. to Report Q2, 2024 Results on Aug 05, 2024

New minor risk - Share price stability

Si-Bone, Inc. Increases Revenue Guidance for 2024

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.32 loss in 1Q 2023)

Insufficient new directors

SI-BONE, Inc., Annual General Meeting, Jun 25, 2024

SI-BONE, Inc. to Report Q1, 2024 Results on May 06, 2024

New minor risk - Profitability

SI-BONE, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: US$1.13 loss per share (vs US$1.79 loss in FY 2022)

Forecast to breakeven in 2026

CEO & Director recently sold €751k worth of stock

SI-BONE, Inc. to Report Q4, 2023 Results on Feb 26, 2024

SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application

Forecast to breakeven in 2026

SI-Bone, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Executive Chairman recently sold €130k worth of stock

SI-BONE, Inc. Increases Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.25 loss per share (vs US$0.41 loss in 3Q 2022)

New major risk - Revenue and earnings growth

SI-BONE, Inc. to Report Q3, 2023 Results on Nov 06, 2023

SI-BONE, Inc. Announces iFuse Bedrock Granite® Implant System Compatibility with Certain Medtronic CD Horizon® Solera 5.5/6.0 System Rods

CEO & Director recently sold €173k worth of stock

Independent Director recently sold €561k worth of stock

SI-BONE, Inc. Revises Revenue Guidance for the Year 2023

Second quarter 2023 earnings released: US$0.30 loss per share (vs US$0.54 loss in 2Q 2022)

SI-BONE, Inc. to Report Q2, 2023 Results on Aug 07, 2023

CEO & Director recently sold €206k worth of stock

SI-BONE, Inc. has completed a Follow-on Equity Offering in the amount of $83.05 million.

First quarter 2023 earnings released: US$0.32 loss per share (vs US$0.52 loss in 1Q 2022)

SI-BONE, Inc. to Report Q4, 2022 Results on Feb 27, 2023

SI-BONE, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022

SI-BONE, Inc. Announces FDA Clearance for Expanded Rod Compatibility with the iFuse Bedrock Granite(R) Implant System

Executive Chairman recently sold €101k worth of stock

Third quarter 2022 earnings released: US$0.41 loss per share (vs US$0.48 loss in 3Q 2021)

SI-BONE, Inc. Updates Revenue Guidance for the Year 2022

SI-BONE, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Executive Chairman recently sold €135k worth of stock

SI-BONE, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Second quarter 2022 earnings released: US$0.54 loss per share (vs US$0.42 loss in 2Q 2021)

SI-BONE, Inc. to Report Q2, 2022 Results on Aug 08, 2022

SI-BONE, Inc. Announces FDA Clearance for Expanded Indication of the iFuse-TORQ® Implant System

SI-BONE, Inc. Receives FDA 510(k) Clearance for iFuse Bedrock Granite

Executive Chairman recently sold €68k worth of stock

First quarter 2022 earnings released: US$0.52 loss per share (vs US$0.37 loss in 1Q 2021)

SI-BONE, Inc. Provides Revenue Guidance for the Full Year 2022

SI-BONE, Inc., Annual General Meeting, Jun 16, 2022

SI-BONE, Inc. Announces New Technology Add-On Payment for Breakthrough Adult Spinal Deformity Treatment

SI-BONE, Inc. to Report Q1, 2022 Results on May 09, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

SI-BONE, Inc. Provides Revenue Guidance for the Full Year 2022

Executive Chairman recently sold €80k worth of stock

SI-BONE, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Executive Chairman recently sold €122k worth of stock

Third quarter 2021 earnings released: US$0.48 loss per share (vs US$0.33 loss in 3Q 2020)

Executive Chairman recently sold €120k worth of stock

Second quarter 2021 earnings released: US$0.42 loss per share (vs US$0.44 loss in 2Q 2020)

SI-BONE, Inc. Provides Earnings Guidance for the Year 2021

Executive Chairman recently sold €52k worth of stock

Si-Bone, Inc. Announces the Introduction of the Si-Bone Simulator Powered by Medability for Ifuse Surgeon Training and Education